Clinical Trial Update: Study of Pembrolizumab Plus Chemotherapy With Lenvatinib for Malignant Pleural Mesothelioma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial studying pembrolizumab plus chemotherapy with lenvatinib for malignant pleural mesothelioma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Pleural Mesothelioma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• LENVIMA (lenvatinib)

Snippet

Sponsor: Hyogo Medical University | Conditions: Malignant Pleural Mesothelioma | Phase 2 | Status: RECRUITING